Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Avoid the tragedy of hepatitis B reactivation in immunosuppressed patients

Nature Clinical Practice Gastroenterology & Hepatology volume 4, pages 128–129 (2007)Cite this article

boxed-textKohrt HE et al. (2006) Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 24: 1003–1016

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hoofnagle JH et al. (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96: 447–449

    Article  Google Scholar 

  2. Yeo W et al. (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62: 299–307

    Article  Google Scholar 

  3. Lok AS et al. (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125: 1714–1722

    Article  Google Scholar 

  4. Esteve M et al. (2004) Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53: 1363–1365

    Article  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rachel Jones, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. and ER Schiff is the Chief of the Division of Hepatology and the Director of the Center for Liver Diseases, JA Foont is a Hepatology Fellow at the Center for Liver Diseases, at the University of Miami School of Medicine, Miami, FL, USA.,

    Julie A Foont & Eugene R Schiff

Authors
  1. Julie A Foont
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugene R Schiff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julie A Foont.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Foont, J., Schiff, E. Avoid the tragedy of hepatitis B reactivation in immunosuppressed patients. Nat Rev Gastroenterol Hepatol 4, 128–129 (2007). https://doi.org/10.1038/ncpgasthep0740

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpgasthep0740

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing